{
    "nctId": "NCT03211572",
    "briefTitle": "The EMPOwER Study Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers",
    "officialTitle": "Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers: The EMPOwER Study",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 82,
    "primaryOutcomeMeasure": "Endocrine Therapy response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Any patient with histologically confirmed newly diagnosed operable ER+, Her2 negative invasive carcinoma on diagnostic core biopsy that has a radiographic size \u2265 1.5 cm\n* Histology has to be ductal, lobular or mixed\n* Surgery date planned in the next 2-6 weeks\n* Negative pregnancy test if of child baring potential\n* Post-menopausal status verified by FSH and Estradiol (with 6 months of amenorrhea)\n\nExclusion Criteria:\n\n* Previous treatment with endocrine therapy, chemotherapy or chest wall radiation within last 6 months\n* Known metastatic or recurrent breast cancer.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}